Cited 0 times in
코로나19 약물치료의 최신지견
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 염준섭 | - |
dc.date.accessioned | 2022-11-24T00:44:41Z | - |
dc.date.available | 2022-11-24T00:44:41Z | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 1975-8456 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190932 | - |
dc.description.abstract | Since the coronavirus disease 2019 (COVID-19) outbreak, more than 150 million people in over 200 countries have been infected, with over 3 million people dying due to it, as of May 1, 2021. Many researchers are working continuously to find effective drug treatments for COVID-19; however, the optimal treatment approach remains unclear. In this article, current advances in pharmacological treatments for patients with COVID-19 are discussed. Data obtained from recent studies indicate a mortality benefit with the administration of dexamethasone or adjunctive tocilizumab and potential clinical benefits with remdesivir (with or without baricitinib). Several monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 have been developed. The US Food and Drug Administration issued two emergency use authorizations: one for bamlanivimab/etesevimab and another for casirivimab/imdevimab for patients with mild to moderate COVID-19, at high risk of progression to severe disease and/or hospitalization. The pathogenesis of COVID-19 indicates that antiviral treatments would be most beneficial in the early phase of the infection that is primarily driven by replication of severe acute respiratory syndrome coronavirus 2, whereas immunosuppressive/anti-inflammatory therapies are likely to be more beneficial during the late phase of the infection, when the disease is driven by an exaggerated immune/inflammatory response to the virus that causes tissue damage. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | Korean | - |
dc.publisher | 대한의사협회 | - |
dc.relation.isPartOf | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION(대한의사협회지) | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | 코로나19 약물치료의 최신지견 | - |
dc.title.alternative | Current advances in pharmacological treatments for patients with COVID-19 | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Sun Bean Kim | - |
dc.contributor.googleauthor | Joon-Sup Yeom | - |
dc.identifier.doi | 10.5124/jkma.2021.64.5.375 | - |
dc.contributor.localId | A02353 | - |
dc.relation.journalcode | J01833 | - |
dc.identifier.eissn | 2093-5951 | - |
dc.subject.keyword | COVID-19 | - |
dc.subject.keyword | Coronavirus infections | - |
dc.subject.keyword | Antiviral agents | - |
dc.subject.keyword | Immunomodulators | - |
dc.subject.keyword | Monoclonal antibodies | - |
dc.contributor.alternativeName | Yeom, Joon Sup | - |
dc.contributor.affiliatedAuthor | 염준섭 | - |
dc.citation.volume | 64 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 375 | - |
dc.citation.endPage | 385 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION(대한의사협회지), Vol.64(5) : 375-385, 2021-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.